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Original Article
Impact of antibiotic restriction on broad spectrum antibiotic usage in the ICU of a
developing country
Shahla Siddiqui1, Kashif Hussein2, Roshan Manasia3, Aijaz Samad4, Nawal Salahuddin5, Afia Zafar6, M. Qamarul Hoda7
Department of Anaesthesia1,4,7, Medicine5, and Microbiology6, Aga Khan University, Karachi. 
Abstract
Objective: To reduce rates of nosocomial pneumonia and cost of antibiotic therapy.
Methods: By means of a policy implementation the following broad spectrum antibiotics were restricted to usage
in the ICU for 72 hours: Cefepime, Meropenem, Imipenem, Tazocin, Polymixin B and Vancomycin, after an
institutional based pharmacy and therapeutic committee approval.  The ICU pharmacist would alert the ICU
residents or consultants after 48 hours of the computer based antibiotic entry that the order would expire within
hours. Telephone approval was obtained followed by a formal consultation if deemed necessary by the ID
specialist or primary team. Antibiotic usage was standardized by defined daily doses (DDDs) per 1000/patient-
days.
Results: A cumulative 34% reduction was seen in the use of all broad spectrum antibiotics in our ICU after the
enforcement of the antibiotic restriction policy. The largest reduction was seen in the use of Tazocin (190 DDDs)
and Meropenem (60 DDDs).  The policy resulted in a reduction by 40% of overall broad spectrum antibiotic
pharmacy costs. The number of multidrug resistant organisms has remained static but the ventilator associated
pneumonia rates have declined. 
Conclusion: Streamlining the formulary to control antibiotic choices and the creation of a restriction program
using the expertise of infectious disease physicians resulted in significant reductions in the use of and
expenditure for broad spectrum antibiotics (JPMA 57:484:2007). 
Introduction
Resistance of common hospital-acquired bacteria to
antibiotics is a worldwide problem.  It can lead to increased
morbidity, mortality, length of hospital stay, and healthcare
expenditures.1 In the setting of an intensive care unit (ICU)
of a developing country where health costs are borne by the
patients and to some extent the hospitals, it is causing a
huge economic burden.2 Our patients are getting sicker due
to the rampant usage of broad spectrum antibiotics leading
to resistance and nosocomial infections with more and more
virulent organisms.3 Acute increases in antibiotic resistance
may be due to antibiotic selection pressures, over-crowding
and other environmental changes, all of which are present
in our setting. The most resistant organisms are found in
units where patients are immuno-compromised, are subject
to invasive procedures or remain for long periods.4
Institutions elsewhere in the world have  enhanced patient
care through therapeutic optimization of the use of
antimicrobial agents through the use of antibiotic restriction
policies implemented widely throughout the hospital.5
Patients suffering from nosocomially acquired
sepsis have a high mortality rate and spend a prolonged
time in the ICU, leading to high direct and indirect costs6,
[AKUH ICU Quality Indictors 2004-5]. Particularly
productivity losses due to premature death represent a
considerable burden to the society and entire families are
destroyed economically. Irrational use of antibiotics is a
direct cause of emergence of such resistant nosocomial
infections and a national healthcare issue with no targeted
interventions present in Pakistan. Studies in the West have
indicated that restriction of usage of some antibacterial
agents is a successful method to decrease antibiotic
consumption and a way to bring cost savings and help
prevent emergence of resistant microorganisms in
hospitals.7 However, no such policies have thus far been
tried in centers here.
International rates for resistant organisms such as
MRSA (methicillin resistant staphylococcus aureus) and
ventilator associated pneumonias (VAP) have been on the
rise. Studies have quoted a rate of 40% with a mortality of
close to 16%.8,9 These are reflected in our Hospital acquired
Infection (HAI) per 1000 patient days rate in the last quarter
prior to the antibiotic restriction policy of 3.89 per 1000
patient days (PD), which has increased from 1.0 /1000 PD.
Similarly our ventilator associated pneumonia rates had
increased in the time period prior to the policy from 1.2 per
1000 PD to 5.3/ 1000 PD. This was above the 50th
percentile of NNIS (National nosocomial infection
surveillance) USA data.10
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have helped in controlling rates of resistant organisms
spread and contain costs in intensive care units across the
world. However it has never been reported in a developing
country such as Pakistan, where resistance trends are on the
rise.
The present study had an objective to show that
restricting the use of broad spectrum antibiotics reduces
rates of usage and cost of antibiotics, as well as shows
reduction in the rates of nosocomial pneumonia.
Materials and Methods
The study was conducted for 6 months from October
2005 till March 2006, in the intensive care unit of a tertiary
care hospital in an urban center of the country, serving a
population of over ten million. It is a multidisciplinary 12
bedded adult ICU. All drug and antibiotic entries are made
centrally by means of a computer based service, linked from
all units of the hospital to the pharmacy.
After formulating an antibiotic restriction policy by
a team comprising of intensivists, infectious disease
specialists, microbiologist and a surgeon, the following
broad spectrum antibiotics11 were restricted to usage in the
ICU for 72 hours: Cefepime, Meropenem, Imipenem,
Tazocin, Polymixin B and Vancomycin. This was
implemented after an institutional based pharmacy and
therapeutic committee approval was obtained. Appropriate
cultures were to be obtained prior to therapy. The ICU
pharmacist would alert the ICU residents or consultants
after 48 hours of the computer based antibiotic entry that the
order would expire within  hours. This was done by means
of a stamp on the chart and verbal indication. At this point
the residents were to obtain 'ID (infectious disease)
approval' from a team of designated ID specialists identified
earlier. Telephone approval was obtained followed by a
formal consultation if deemed necessary by the ID specialist
or primary team. No cost was incurred to the patient if only
an approval was sought.  In case of approval being denied
or not obtained the antibiotic would auto- discontinue (auto-
d/c).
Although antibiotic control programs have been
successful in other countries, this represents the first attempt
at successful antibiotic control in a large Pakistani teaching
hospital.12 The Antibiotic restriction policy was enforced
from January 1st 2006. Therefore, we looked at data 3
months before and 3 months after the policy
implementation (two quarters).
Antibiotic usage was standardized by defined daily
doses (DDDs) per 1000/patient-days.13 It is an international
unit for drug utilization measurement and is defined as "the
average maintenance dose per day for a drug used for its
main indication" This has been assigned by the WHO
(World Health Organization) Collaborating center for drug
statistics methodology.14-19 It enables the researcher to
access trends in drug consumption based on
inventory/distribution data and is a technical measurement
unit that allows comparison. 
DDD = No. of Units used x no. of grams per unit /
DDD of antibiotic in grams.
'Patient days' were defined as occupied bed - days or :
No. of beds x  occupancy x no. of days17
All data were entered into SPSS version 14 and
analyzed. Data analysis was done by unpaired t-testing with
a confidence interval of 95% and a p of < 0.05 significant. 
Cost data were expressed in rupees and percentage
of prior use. Changes in antibiotic usage was determined by
comparing the total usage in two blocks of October -
December 2005 and January - March 2006 when the
streamlined formulary and restricted group of antibiotics,
controlled by the Infectious Disease (ID) and ICU teams
were initiated. 
Results
Our compliance of antibiotic restriction policy was
89%, whereby 89% of the time the policy was adhered to and
on other occasions either no approval was obtained or the
primary team deferred continuation of the drug. Figure 1
shows comparative data of the two time periods being
reviewed and the impact on various antibiotics and their
number of daily defined doses (DDD) per 1000 patient days.
Apart from Vancomycin and Amikacin, the use of which
went up by 45 points and  points respectively all other
antibiotics showed a reduction in the DDD. A cumulative
34% reduction was seen in the use of all broad spectrum
antibiotics in our ICU after the enforcement of the antibiotic
restriction policy. The largest reduction was seen in the use
of Tazocin (190 points) and Meropenem (60 points). 
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Figure 1. Impact of antibiotic restriction policy (ICU) on DDD /1000 patient days.
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Figure 2 shows the impact on number of units of
antibiotics per patient days. Again there is an overall
reduction of 33% in the usage with the exception of
vancomycin. Taking a Confidence interval of 95% and 0.05
as the significant value of p, this  proved significant (p value
of 0.04) by Student's t-test analysis. 
The successful implementation of the model resulted
in a reduction by 40% of   overall pharmacy broad spectrum
antibiotic costs, as shown in Figure 3. The cost of
vancomycin went up by a modest 22%, however Tazocin
and Meropenem showed a decline of 46% and 29%
respectively.  
We also monitored the growth of multidrug resistant
organisms such as MRSA, VRE (vancomycin resistant
enterococcus), Acinetobacter, Enterobacter, Pseudomonas
and Klebsiella. The incidence has remained static however
the cumulative VAP rates, defined as a positive culture by
tracheal aspirate or broncho-alveolar lavage (BAL) with
chest X-ray findings or clinical correlation on a patient who
is being mechanically ventilated has gone down from 5.3 to
2.3 HAI /1000 PD in the quarter following the policy
implementation.
Discussion
An antibiotic restriction program constituted an
effective and cost-saving strategy to optimize antibiotic use
in a tertiary care center ICU, improving cost and emergence
of multi drug resistant organisms as well as ventilator
associated pneumonia rates and significantly reduced the
usage of broad spectrum antibiotics.  In a developing
country where resources are limited antibiotic prescription
patterns limiting the use of different antimicrobials should
be promoted to reduce the selection pressure that aids the
development of resistance.20 This in turn would reduce
length of stay and severity of illness amongst the critically
ill patients and also the cost incurred.21 Surprisingly the use
of Vancomycin, a glycopeptide antibiotic particularly used
for MRSA, went up increasing the cost as well during the
study period, however this may correlate to the slight
reduction seen in MRSA and VAP rates in the ICU.
Although the trends are favourable, a review of simply one
quarter is insufficient to reach a definitive conclusion,
however, it is a step in the right direction.
Streamlining the formulary to control antibiotic
choices and the creation of a restriction program using the
expertise of infectious disease physicians resulted in
significant reductions in the use of and expenditure for
broad spectrum antibiotics. Problems faced were delay in
drug order processing and drug delivery by pharmacy if
continuation was decided. There was often confusion about
who will take the ID approval whether it would be the ICU
team or the primary team. Ours is an open ICU where
patients are admitted by primary teams and managed
conjointly by the intensivist and an ICU team as well as
looked over by the primary team. The therapeutic use of 2nd
line agents increased and the compliance rate is also on the
incline. Despite these problems this program proved
successful and there was an overall reduction in the
pharmacy costs which make up a large part of the patient
bill.
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Umbilical cord prolapse - A review of diagnosis to delivery interval on perinatal and
maternal outcome
Rozilla S. Khan, Tahira Naru, Faryal Nizami
Department of Obstetrics and Gynaecology, Aga Khan University Hospital, Karachi, Pakistan.
Abstract
Objective: To determine the significance of the Diagnosis to Delivery Interval (DDI) on perinatal outcome and
maternal complications in patients with umbilical cord prolapse. 
Methods: This was a case series of 44 patients identified with "Umbilical cord prolapse" during a 10-year period
at the Aga Khan University Hospital. Data was retrieved for gestational age, foetal presentation, DDI, incision to
delivery time, delivery method, apgar score, birth weight and outcome, and maternal complications. The
influence of DDI on perinatal mortality, apgar scores at 5 minutes, neonatal intensive care unit (NICU) admission
and maternal complications resulting from mode of delivery with cord prolapse was assessed. 
Results: The hospital based incidence of cord prolapse was 1.4 per 1000 deliveries. The mean DDI was 18
minutes, with 64% of women delivering within this time. Of the 13(29 %) neonates transferred to NICU with < 7
apgar score at 5 minutes, 10/13(76%) delivered within the mean DDI. There were 4 perinatal deaths, of which 2
were term pregnancies with birth asphyxia, whereas 2 were < 28 weeks. There was no statistically significant
impact of DDI on 5-minute apgar scores, perinatal mortality, NICU admissions and maternal complications in
patients with cord prolapse 
Conclusions: DDI may not be the only critical determinant of neonatal outcome. Most neonates with poor apgar
scores had DDI within the average time. Artificial rupture of membranes should be performed cautiously with pre-
existing CTG trace abnormalities. In-utero resuscitative measures may help reduce further cord compression
and improve outcome (JPMA 57:487:2007). 
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